Share on StockTwits

Analysts’ ratings reiterations for Friday, August 8th:

Apollo Investment Corp. (NASDAQ:AINV) had its neutral rating reiterated by analysts at Citigroup Inc.. The firm currently has a $8.50 target price on the stock, up from their previous target price of $8.00.

Amkor Technology (NASDAQ:AMKR) had its buy rating reaffirmed by analysts at Citigroup Inc.. The firm currently has a $11.50 target price on the stock, up from their previous target price of $8.25.

Anacor Pharmaceuticals (NASDAQ:ANAC) had its buy rating reissued by analysts at Jefferies Group. The firm currently has a $25.00 price target on the stock, up from their previous price target of $24.00.

Arista Networks (NASDAQ:ANET) had its buy rating reaffirmed by analysts at Citigroup Inc.. The firm currently has a $90.00 target price on the stock, up from their previous target price of $70.00.

Ariad Pharmaceuticals (NASDAQ:ARIA) had its sell rating reissued by analysts at Citigroup Inc.. The firm currently has a $5.00 price target on the stock, down from their previous price target of $7.00.

Blucora (NASDAQ:BCOR) had its buy rating reiterated by analysts at Zacks. Zacks currently has a $27.00 price target on the stock, down from their previous price target of $28.00. The analysts wrote, “Blucora (BCOR-Buy, PT from $28 to $27) reported slightly better-than-expected 2Q14 results, driven by modest upside in Tax and Search & Content. “Shares, unfortunately, will likely suffer near-term due to an overly aggressive consensus, despite 3Q guidance matching our recently revised projections minus some incremental additional spending in Tax, as the street largely ignored the recent trends in the affiliate search space, with 2015 appearing particularly egregious. However, while IAC (IACI-Buy) and Perion (PERI-Buy) are expecting significant step-downs in 3Q search revenue, we believe 2Q represents the reset quarter for Blucora, with 3Q possibly marking a bottom for consolidated search, although O&O revenue is likely to begin growing sequentially next quarter. “We are reserving judgment on Monoprice until 4Q, but even now assigning a discounted multiple of 9x while maintaining our industry multiples of 5x for Search and 11x for Tax, we still arrive at sum-of-the-parts valuation of $27 per share in value, or at least $24 excluding our conservative PV valuation for Blucora’s $723 million in NOLs.”

Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE) had its neutral rating reissued by analysts at Citigroup Inc.. They currently have a $72.00 target price on the stock, down from their previous target price of $83.00.

Denbury Resources (NYSE:DNR) had its neutral rating reaffirmed by analysts at Citigroup Inc.. The firm currently has a $17.60 target price on the stock, down from their previous target price of $17.90.

Himax Technologies, Inc. (NASDAQ:HIMX) had its buy rating reaffirmed by analysts at Topeka Capital Markets.

Lululemon Athletica inc. (NASDAQ:LULU) had its positive rating reiterated by analysts at Deutsche Bank.

NVIDIA (NASDAQ:NVDA) had its underperform rating reiterated by analysts at Morgan Stanley. Morgan Stanley currently has a $15.00 price target on the stock, up from their previous price target of $14.00. The analysts wrote, “In-line revs, but GM upside and slightly better revenue outlook surprised us, given inventory reduction at competitor, AMD. As spot shortages ease we think GMs come back a bit. The company is executing well but we see the stock as expensive, and remain UW, albeit with higher PT.”

PhotoMedex (NASDAQ:PHMD) had its hold rating reaffirmed by analysts at Maxim Group.

Tekmira Pharmaceuticals (NASDAQ:TKMR) had its hold rating reissued by analysts at Maxim Group. Maxim Group currently has a $23.00 price target on the stock.

Zynga (NASDAQ:ZNGA) had its outperform rating reissued by analysts at Credit Suisse. The firm currently has a $6.00 target price on the stock, down from their previous target price of $7.00. The analysts wrote, “Q2 bookings and EPS were at the low end of guidance, reflecting delays. Bookings were $175 million, vs. our estimate of $195 million, consensus of $191 million, and guidance of $175 – 195 million. Non-GAAP EPS was $0.00, vs. our estimate of $0.01, consensus of $0.00, and guidance of $0.00 – 0.01. Core titles appeared to perform well, but no new major games launched, apart from FarmVille 2 on mobile. We believe guidance contemplated another release late in Q2.”

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.